Idarubicin is an anthracycline antileukemic agent widely used in the treatment of hematological malignancies. However, cardiotoxicity and secondary leukemia have been reported after idarubicin treatment. Dexrazoxane is the only medication approved by FDA to prevent anthracycline-evoked cardiotoxicity. However, lack of information on the genomic damage caused by the combination of these 2 drugs prompted us to conduct the current study. We treated mice with different doses of idarubicin and/or dexrazoxane. Genomic DNA damage, apoptosis, and reactive oxygen species (ROS) were evaluated in the bone marrow cells. Our results demonstrate that mice pretreated of with dexrazoxane had significant lower genomic damage, apoptosis and ROS generation compared with that of mice treated with idarubicin alone, an effect that was dependent on dexrazoxane dose. The expression of 84 genes implicated in DNA damage-signaling pathways was quantified using an RT 2 Profiler PCR Array. Idarubicin treatments altered the expression of 58 genes, and 16 of those were expressed at significantly different level. In treatments combining idarubicin and dexrazoxane, substantial restorations of mRNA expression of these genes were observed. RT-qPCR was performed for selected genes and the alteration of these genes was confirmed. Alterations in mRNA expression of a subset of genes were further proved by Western blotting analysis of protein levels, which nearly showed similar alterations. Conclusively, dexrazoxane can be safely co-administered with idarubicin. Moreover, dexrazoxane minimizes idarubicin-evoked genomic damage via its radical scavenging and DNA repairenhancing activities. Thus, dexrazoxane may help avert secondary malignancies in cancer patients in remission who are exposed to idarubicin.
Idarubicin (4-demethoxydaunorubicin), a second-generation anthracycline analog, is an anticancer agent used in the treatment of certain hematological malignancies (Hortobagyi, 1997) . It induces a wide range of biochemical responses in living cells, including cytotoxicity. This property of idarubicin, used to kill tumor cells, is attributed to its DNA intercalating abilities and its ability to poison topoisomerase IIa (Binaschi et al., 1997) . Moreover, idarubicin's structure is a target for cytochrome P450 reductases, which generate reactive oxygen species (ROS) and induce cellular nonDNA and DNA damage (Celik and Arinc, 2008) . Although idarubicin exhibits reduced cardiotoxicity and possesses unique features that distinguish it from other, more toxic, anthracyclines, it can still cause pernicious adverse effects.
Therapy-related leukemia with the del(7)(q22) mutation was reported in bone marrow cells after chemotherapy that included idarubicin (Kim et al., 2011) . Moreover, therapy-related acute myeloid leukemia has been observed after idarubicin was used in combination with cytarabine to treat primary pulmonary leiomyosarcoma with skin metastasis (Ma et al., 2011) . Cytogenetic testing in bone marrow cells also showed trisomy 8 in a woman who received 3 courses of systemic chemotherapy that included idarubicin (Venizelos et al., 2007) . The consistent association of idarubicin with therapy-related acute leukemia that possesses mixed-lineage leukemia gene rearrangements suggests that such translocations may cause acute leukemia (Hasan et al., 2014) .
Cell metabolism of idarubicin can lead to the generation of reactive metabolites, which can damage genomic DNA and cause genotoxicity (Celik and Arinc, 2008) . It has been shown that idarubicin can also cause oxidative stress-mediated DNA damaging effects and apoptosis in both normal and leukemic cells (Majsterek et al., 2005) . Moreover, it is believed that idarubicin/metal-ion complexes can generate reactive metabolites that can also induce genotoxicity and prevent the process of DNA repair, resulting in the inactivation of tumor suppressor genes and leading to the induction of secondary malignances. Thus, treatments with chemotherapy need to be amended, and other supporting therapies must be examined to diminish unwanted side effects and to afford a better quality of life to survivors. In this framework, it was proposed that dexrazoxane may be beneficial because it undergoes hydrolysis to ADR-925, which has an ethylenediaminetetraacetic acid-like structure, and chelates iron, thus decreasing the number of idarubicin/ iron complexes and subsequently reducing the formation of reactive metabolites produced by idarubicin (Buss and Hasinoff, 1993) . In fact, dexrazoxane has been found to decrease the risk of anthracycline-evoked heart failure and to enhance anticancer responses to anthracyclines (Wu, 2015) . However, in addition to heart failure, genomic damage and development of secondary tumors should be taken into account as adverse effects of idarubicin treatment.
Providing protection against genomic damage in normal cells represents a promising approach to overcome the unescapable adverse effects of chemotherapy, which will allow the safe use of increased anticancer drug doses for the benefit of future cancer survivors. We posited that dexrazoxane is useful in attenuating idarubicin-evoked genomic damage that can play a role in generating secondary tumors from normal cells. Thus, the current work was conducted to examine the impact of dexrazoxane on idarubicin-evoked genomic damage and apoptosis in nontumor cells. Moreover, its effect on gene expression profiling associated with the DNA damage response was elucidated. The mouse bone marrow micronucleus test accompanied with fluorescence in situ hybridization (FISH) assay, and alkaline single cell gel electrophoresis (comet assay) were performed to evaluate the genomic DNA damage of this combination. Apoptosis in mouse bone marrow cells was analyzed by using an annexin V assay and determining the presence of hypodiploid DNA content. Production of ROS was also evaluated by the oxidant-sensing fluorescent probe, 2 0 ,7 0 -dichlorodihydrofluorescein diacetate. The expression levels of 84 genes implicated in DNA damage signaling pathways were quantified using an RT 2 Profiler PCR Array. Array results were validated with selected genes by real-time reverse transcription quantitative polymerase chain reaction (RT-qPCR). Western blot analysis was also used to corroborate the changes in the expression of genes of interest, which was used to determine whether alterations in gene expression at the mRNA level were reflected in alterations at the protein level.
MATERIALS AND METHODS
Animals. Male BALB/c mice aged 10-14 weeks and weighing 20-25 g were used in the current experiments. Mice were acquired from the Experimental Animal Care Center, King Saud University. They were maintained under standard laboratory conditions of relative humidity (45%-55%), temperature (23 C-25 C), and light (12-h light/12-h dark), with free access to standard mouse pellet diet and tap water throughout the experimental period. All experimental protocols described in the article were duly approved by the Institutional Animal Care and Use Committee of King Saud University and were conducted in accordance with NIH guidelines. Each vehicle control group and treatment group consisted of a minimum of 6 randomly assigned mice.
Drugs and treatment. Idarubicin and dexrazoxane were purchased from Sigma-Aldrich Chemical Company (Saint Louis, Missouri, USA). All other chemicals were of the finest analytical grade. They were dissolved in 5% dimethyl sulfoxide (DMSO) in distilled water and were intraperitoneally injected within 20 min of preparation. The administered volume was 0.1 ml/10 g body weight. Idarubicin was injected at doses of 3, 6, and 12 mg/ kg body weight. The injected doses of idarubicin were chosen based on its ability to induce genomic damage in mice (Attia, 2011; de Campos Nebel et al., 2002) . Dexrazoxane (75 and 150 mg/kg) was administered intraperitoneally 30 min prior to idarubicin injection. These doses of dexrazoxane have been found to be the optimal preventive doses against genetic alterations evoked by anthracyclines and podophyllotoxins in mice and are corresponding to clinically relevant doses in humans of 225 and 450 mg/m 2 , respectively (Attia et al., , 2016c Bakheet et al., 2011; Hofland et al., 2005) . The selected doses are within the dose range used for human chemotherapy. Idarubicin is typically administered in doses of 10-15 mg/m 2 for multiple days, depending on the regimen in which it is being used. Idarubicin 40 mg/m 2 is also given as one high dose/cycle for leukemia induction (Weiss et al., 2002) . Mice have a body weight/surface area ratio of approximately 3 kg/m 2 . Therefore, the highest dose of 12 mg/kg used in the current experiment corresponds to approximately 36 mg/m 2 and is within the dose range used for human chemotherapy. Control mice were administered equal volumes of 5% DMSO in distilled water.
Mouse bone marrow micronucleus test. Twenty-four hours after dexrazoxane and/or idarubicin injection, the animals were euthanized by cervical dislocation. Both femurs were excised, and the femur bone marrow cells were flushed into fetal bovine serum and then pelleted by centrifugation at 1100 Â g for 5 min. Groups of mice that were injected intraperitoneally with 2 mg/ kg of mitomycin C or colchicine (Sigma-Aldrich, Saint Louis, MO, USA) 24 h before euthanasia were considered clastogen and aneugen positive controls, respectively (Attia, 2009) . Mouse bone marrow was smeared on a minimum of 4 microscopic slides per mouse, and the slides were left to dry at room temperature. One microscope slide for each animal was stained with May-Grü nwald and Giemsa solutions for conventional estimation of the micronucleated polychromatic erythrocyte (MNPCE) frequencies (Adler, 1984) . The remaining, microscope slides were kept at À20 C to discriminate between clastogenicity and aneugenicity by recognizing the origin of micronuclei (MN) by FISH analysis using labeled centromeric DNA probe as previously described (Attia et al., 2003) . Moreover, the number of polychromatic erythrocytes (PCE) among 1000 normochromatic erythrocytes (NCE) for each mouse was recorded to estimate bone marrow suppression as described previously (Adler, 1984) .
Alkaline comet assay. In the time course investigation, the animals were euthanized by cervical dislocation 3 and 24 h after injections of idarubicin and/or dexrazoxane. A group of mice that orally received 100 mg/kg of methanesulfonate (EMS; Sigma-Aldrich, Saint Louis, MO, USA) 24 h before euthanasia was considered a genotoxicant positive control (Bakheet et al., 2011) . Femur bone marrow cells were harvested as described above, and then washed with cold phosphate buffered saline. Marrow cells (approximately 10 000 cells) were mixed with 0.75% agarose (lowmelting point) and were spread on a microscope slide, precoated with 1.5% normal melting point agarose. Another layer of lowmelting point agarose was applied, the slides were covered with a coverslip, and the agarose was solidified on ice. The coverslip was discarded, and the slides were slowly lowered into ice-cold lysis buffer and stored at 4 C overnight. Unwinding of the DNA, electrophoresis, and staining of the microscopic slides were performed as described previously (Attia et al., 2013) . Sixty minutes after staining, the nucleoids were evaluated with a Nikon fluorescence microscope. Two slides for each mouse were prepared, and 100 cells were randomly selected from each slide and subjected to image analysis by Comet Assay IV software (Perceptive Instruments, Suffolk, England). The level of DNA damage was determined using tail intensity (%).
Detection of apoptosis. In order to examine the effect of dexrazoxane on idarubicin-evoked apoptosis, 4 groups of 10 animals per group were injected with 150 mg/kg dexrazoxane and/or 12 mg/kg idarubicin and euthanized 24 h later. The marrow cells were harvested, and apoptosis was detected with propidium iodide (PI) based on the method by Nicoletti et al. (1991) , with some changes as previously described in Saquib et al. (2012) . Moreover, annexin V-fluorescein isothiocyanate/PI double staining was used to quantify late and early apoptotic cells as previously described (Attia, 2012) . The stained bone marrow cells were then evaluated by flow cytometry (FACSCalibur; BD Biosciences). The proportions of late and early apoptotic cells were quantified using CellQuest (BD Biosciences).
Determination of ROS levels. To examine the impact of dexrazoxane on idarubicin-evoked ROS production, bone marrow cells (approximately 2 Â 10 5 ) were from the same mice used in the detection of apoptosis. The production of ROS was assessed based on the intracellular peroxide-dependent oxidation of 2 0 ,7 0 -dichlorodihydrofluorescein diacetate to produce the fluorescent product, 2 0 ,7 0 -dichlorofluorescein (DCF), as described previously in Attia (2012) . Data are presented as fold-differences relative to the untreated control.
Gene expression analyses. In order to better explore the protective properties of dexrazoxane against genomic damage evidenced by comet and MN assays, we also assessed the expression of genes related to DNA damage response. Gene expression analysis was performed on bone marrow cells 24 h after treatment with idarubicin and/or dexrazoxane, using the RT 2 Profiler PCR Array and RT-qPCR. Mouse treatment was the same as it was for apoptosis quantification. Femur bone marrow cells were harvested from the animals and placed on ice before and after the isolation procedure. To collect the cells, bone marrow was flushed from both femurs into clean, autoclaved, 8-ml glass tubes and centrifuged at 10 000 Â g for 5 min, after which the supernatants were discarded. Total RNA was extracted from the resultant pellets with an RNeasy Mini Kit (Qiagen, Valencia, California, USA), following the manufacturer's protocol. To remove any contaminating genomic DNA, samples were treated with DNase (Qiagen, Valencia, California, USA) at 42 C for 10 min during the RNA extraction procedure. The quality and quantity of isolated RNA were measured with a ScanDrop Nano-Volume Spectrophotometer (Analytik Jena AG, Jena, Germany). Additionally, RNA integrity was assessed by electrophoresis on 1% agarose gels by the Optigo Imaging System (Isogen Life Science, De Meern, The Netherlands).
Gene expression profiles. Alterations in the relative gene expression of 84 genes associated with ATM/ATR Signaling network, DNA damage and repair, apoptosis, and the cell cycle were quantified using an RT 2 Profiler PCR Array Mouse DNA Damage
Signaling Pathway (Qiagen, Valencia, California, USA) in a 96-well plate. An equal amount of RNA (2 mg) was used to synthesize complementary DNA (cDNA) using an RT 2 First Strand Kit (Qiagen, Valencia, California, USA), as described in the manufacturer's protocol. Catalogued array plates for PCR array analyses were acquired from Qiagen (Catalog number PAMM-029Z), and the cDNA was applied to the PCR array plate along with the RT master mix. RT 2 Profiler PCR Array reactions were conducted on an ABI Prism 7500 real-time PCR system (Applied Biosystems, California, USA) with an initial denaturation step at 95 C for 10 min, followed by 40 cycles of denaturation at 95 C for 15 s and annealing/extension at 60 C for 1 min. The melting curve stages were from 60 to 95 C, which were performed according to the manufacturer's instructions. The C T values (cycle threshold) for each sample were set automatically by the thermal cycler according to the amplification curves. The baseline and threshold values were manually set as recommended by the RT 2 Profiler PCR Array user manual.
Results were evaluated by RT 2 Profiler PCR Array Data Analysis version 3.5. Expression data obtained with dexrazoxane and/or idarubicin treatment groups were normalized to the average C T value of the 5 housekeeping genes (B2m, Actb, Gapdh, Gusb, and Hsp90ab1, included in the array to minimize functional biases) and were expressed relative to the solvent control group. A heat map was generated using the web-based program of the RT Analysis provided by the manufacturer. Only genes that were statistically different from the solvent control group (Student's t-test, p < .05), and showed a fold regulation ! 1.5 relative to the control group were considered in the analyses.
Confirmative gene expression study using RT-qPCR. RT-qPCR analyses were conducted to confirm that the previous results of selected genes found by the RT 2 Profiler PCR Arrays analysis to be expressed at statistically significant different levels in bone marrow cells from treated and control mice. These genes were Ppp1r15a, Bax, Xrcc1, Trp53, Ogg1, and Exo1. RT-qPCR was performed using an ABI Prism 7500 real-time PCR system using the following program: 60 s at 95 C, followed by 40 cycles of 15 s at 95 C, and 45 s at 60 C. The reverse transcription reaction and RT-qPCR amplification were performed as described previously in Attia et al. (2013) . The endogenous reference gene, Cyclophilin A, was used as an internal reference to calculate the relative expression of the target genes between control and treated animals. RT-qPCR results were analyzed using the relative gene expression (ie, DDC T ) method, as explained and described previously in Livak and Schmittgen (2001) .
Western blot analysis. Western blotting was performed to assess the relative protein levels of some of the genes found by the RT Profiler PCR Array analysis to be expressed at statistically significant altered levels in bone marrow cells of treated and untreated mice. Moreover, other DNA damage-related proteins were selected for analysis because of their significance in DNA damage and repair. These proteins are involved in ATM/ATR signaling (Trp53, Parp1), nucleotide excision repair (Ogg1, Trp53), base-excision repair (Ogg1, Parp1, Trp53), mismatch repair (Exo1), double strand break repair (Xrcc1, Trp53), apoptosis (Bax, Ppp1r15a, Trp53), cell cycle (Ppp1r15a, Trp53), and the other DNA repair genes Atrx and Pttg1. Total proteins were isolated from bone marrow cells with RIPA lysis buffer containing protease inhibitors. The lysates were placed on ice for 60 min with intermittent vortexing every 10 min, and then centrifuged at 14 000 Â g at 4 C for 10 min. The supernatant RIPA-soluble fraction was kept at À80 C for later use and the RIPA-insoluble fraction was discarded. Total protein in the supernatant RIPA-soluble fraction was measured by the Lowry technique (Lowry et al., 1951) .
Western blotting was performed as described previously in Ahmad et al. (2015) , with slight modifications. Briefly, 25 mg of total protein from each sample was separated by 7.5 (for Atrx, Parp1, Xrcc1, and Exo1 proteins) to 10% (for Ppp1r15a, Bax, Trp53, Ogg1, and Pttg1 proteins) sodium dodecyl sulfate-polyacrylamide gel. Proteins were electrophoretically transferred into nitrocellulose membranes (Bio-Rad Laboratories, Hercules, USA). The membranes were blocked overnight with 5% nonfat milk solution at 4 C. Protein blots were incubated for 2 h with primary antibodies against Ppp1r15a, Bax, Xrcc1, Trp53, Exo1, Ogg1, Parp1, Atrx, and Pttg1, followed by incubation with peroxidase-conjugated secondary antibodies at room temperature for 60 min. Mouse monoclonal antib-actin (Abcam, Cambridge, Massachusetts, USA) was used as the loading control. Protein bands were then detected using Luminata Western HRP Chemiluminescence Substrates (GE Health Care, Mississauga, Canada), and then visualized and quantified on a C-DiGit Blot Scanner (LI-COR Inc. USA). 
RESULTS

Results of the MN Test
The results of the MN test are presented in Table 1 and Figure 1 , which show that the incidence of MNPCE in the groups treated with the positive control mutagens, colchicine and mitomycin C, was significantly greater than that in the solvent control group (Figure 1 ). Dexrazoxane (75 and 150 mg/kg) caused no alteration in the frequency of MNPCEs compared with that of the solvent control (Table 1 and Figure 1 ). Administration of idarubicin produced dose-dependent increases in the frequency of MNPCE (Table 1) , as well as a significant increase in centromere-positive and centromere-negative MNPCE, demonstrating the induction of both aneugenic and clastogenic effects (Figure 1 ). Furthermore, idarubicin caused a significant reduction in the mitotic activity (Table 1 ). Dexrazoxane pretreatment reduced the incidence of MNPCE in idarubicininjected mice compared with that observed with the corresponding dose of idarubicin alone, and higher doses of dexrazoxane reduced the frequency of MNPCEs more effectively. Moreover, the mitotic activity in these mice significantly increased relative to that in the idarubicin-treated mice, an effect that was dexrazoxane dose-dependent. Additionally, both aneugenic and clastogenic effects evoked by idarubicin injection were decreased by dexrazoxane pretreatment (Figure 1) . 
Results of Alkaline Comet Assay
The results of the alkaline comet assay are presented in Table 2 . Dexrazoxane treatment at either dose did not result in any statistically significant differences in the level of DNA damage compared with that of solvent controls. The level of DNA damage recorded in animals treated with the positive control substance, EMS, was significantly greater than that in the untreated control group (49.56 6 13.12; p < .01). Mice treated with idarubicin presented a significant dose-dependent increase in the level of DNA damage at both sampling times relative to the control mice. When sampled 24 h after idarubicin treatment, mice pretreated with dexrazoxane exhibited significant decreases in the level of DNA damage evoked by idarubicin injection compared with that of idarubicin alone. The higher dose of dexrazoxane provided more protection against DNA strand breaks. However, when sampled 3 h posttreatment, the levels of DNA damage in dexrazoxane-pretreated mice were similar to those in the nonpretreated mice. This suggests that dexrazoxane has no influence on the frequency of early DNA damage evoked by idarubicin ( Table 2) .
Effect of Dexrazoxane on Idarubicin-Evoked Apoptosis
As shown in Table 3 , dexrazoxane was not apoptogenic at the tested dose. Conversely, significant increases in the early and late apoptotic cells were observed in mice injected with idarubicin in comparison with those in the control mice (p < .01). In contrast, mice pretreated with 150 mg/kg dexrazoxane exhibited a statistically significant decrease in the proportion of late and early apoptotic cells compared with those from mice treated with idarubicin (p < .05). Likewise, the proportion of sub-G 1 peaks did not show any significant difference between dexrazoxane-treated and control mice (Figure 2 ). In comparison with that of the untreated control, the proportion of bone marrow cells with sub-G 1 peaks was significantly higher in the idarubicin-treated group (p < .01). Mice pretreated with dexrazoxane showed a significant decrease in the level of the sub-G1 peaks induced by idarubicin compared with the level from mice treated with idarubicin alone (p < .05).
Effect of Dexrazoxane on Idarubicin-Evoked ROS Generation
The generation of ROS in bone marrow cells was assessed by measuring the fluorescence intensity of DCF. No significant alteration in DCF intensity was observed in bone marrow cells after dexrazoxane treatment compared with that of the control (Figure 3) . However, the DCF intensity in animals treated with idarubicin significantly increased compared with that of the untreated control animals (p < .01). However, the idarubicinevoked generation of ROS was profoundly mitigated by dexrazoxane pretreatment and was reduced to a level that was significantly different from the level of ROS in the idarubicintreatment group (p < .05).
Results of Gene Expression Analysis
To explain the molecular targets related to genetic alterations affected by drug treatment, RT 2 Profiler PCR Arrays were run on bone marrow cells of mice injected with dexrazoxane and/or idarubicin as well as untreated control mice (Figure 4 ). Figure 4 shows heat maps that represent the fold regulation expression levels between dexrazoxane and/or idarubicin and the untreated control mice. The heat maps show both up-and down-regulation of mRNA transcripts. Numerous green data are shown in the heat maps, indicating that the expression of such genes was down-regulated in the mouse bone marrow cells. The heat maps also show red data, indicating that the expression of the relevant genes was up-regulated. A tested gene was considered differentially expressed in animals injected with these drugs if there was a >1.5-fold difference in gene expression with a threshold p-value of .05. Administration of dexrazoxane alone altered the expression of 45 of the 84 tested genes. Ten genes had their expression reduced (Abl1, Bax, Pms2, Prkdc, Rad1, Rad51, Rad51b, Topbp1, Trp53bp1, and Ung), whereas 35 genes were over-expressed (Atm, Atr, Atrx, Blm, Brca2, Cdkn1a, Chek1, Dclre1a, Ercc2, Fanca, Fancc, Fancg, H2afx, Hus1, Lig1, Mbd4, Mif, Mlh1, Msh3, Nthl1, Ogg1, Parp1, Parp2, Pcna, Pole, Polh, Rad21, Rad51c, Rad52, Rnf8, Smc1a, Wrn, Xrcc1, Xrcc2, and Xrcc3). However, none of the changes was statistically significant in comparison with that of the solvent control group, except that of Topbp1 (Table 4) . Conversely, examination of the heat maps of gene expression after idarubicin treatment alone, suggests that DNA damage responses occurred. Nineteen of the DNA damage genes were upregulated by idarubicin treatment (Bax, Blm, Brca2, Cdc25c, Cdkn1a, Fanca, Gadd45a, Gadd45g, Nthl1, Parp1, Parp2, Pcna, Pole, Poli, Ppp1r15a, Prkdc, Smc1a, Trp53, and Wrn); however, only the p values for 7 genes indicated statistical significance (Table 4) . Those genes were Bax, Cdkn1a, Gadd45a, Gadd45g, Parp1, Ppp1r15a, and Trp53. Additionally, a large number (39) of the DNA damage repair genes were down-regulated (Abl1, Atrx, Brca1, Brip1, Chek1, Ddb2, Ercc1, Ercc2, Exo1, Fancd2, Fancg, H2afx, Hus1, Lig1, Mbd4, Mlh3, Mpg, Mre11a, Msh2, Msh3, Ogg1, Pms2, Rad1, Rad17, Rad51, Rad51b, Rad52, Rad9a, Rev1, Rpa1, Sumo1, Terf1, Topbp1, Ung, Xpc, Xrcc1, Xrcc2, Xrcc3, and Xrcc6). As mentioned above, a 1.5-fold or greater change in expression with p < .05 was considered significant. Only 9 of the 84 tested genes in the RT 2 Profiler PCR Array were differentially down-regulated at significant levels in bone marrow cells of idarubicin-treated mice. Those genes were Atrx, Exo1, Ogg1, Rad17, Rad9a, Terf1, Topbp1, Ung, and Xrcc1 (Table 4) . On the other hand, when dexrazoxane was administered prior to idarubicin treatment, the mRNA expression of these downregulated genes was restored and the expression of the upregulated genes was reduced. Additionally, 6 genes (Ogg1, Rad51, Terf1, Fen1, Xpc, and Xrcc6) were differentially upregulated at statistically significant levels in bone marrow cells from dexrazoxane-pretreated mice (Table 4) . RT-qPCR was used to corroborate the RT 2 Profiler PCR Array results of some genes found expressed at significantly different levels between treated and control mice. As seen in Figure 5 , dexrazoxane-treated animals did not show significant alterations in the mRNA expression of Bax, Ppp1r15a, Trp53, Exo1, or Xrcc1, but a statistically significant increase in the expression of Ogg1 gene was observed after dexrazoxane treatment compared with that of control animals. The expression of Bax, Ppp1r15a, and Trp53 significantly increased after idarubicin treatment compared with those of the control animals; conversely, clear decreases in the expression of Ogg1, Exo1, and Xrcc1 were observed, indicating an inhibition of DNA repair by idarubicin. With regard to the mice pretreated with dexrazoxane, significant restorations of mRNA expression of the altered genes were observed ( Figure 5 ), which further confirmed the results of the RT 2 Profiler PCR Array. 
Results of Western Blot Analysis
Western blotting analyses were then performed to examine the correspondence between mRNA and protein expression levels of a subset of up-and downregulated genes that were detected by the RT 2 Profiler PCR Arrays. Specific genes were chosen based on their associated proteins having different functions in the DNA-damage signaling pathway. The proteins studied were translated from the Ogg1, Trp53, Parp1, Exo1, Xrcc1, Bax, Ppp1r15a, Atrx, and Pttg1 genes. Representative blots for each tested protein and corresponding b-actin blots are presented in Figure 6A . Results of the densitometric analyses are shown in Figure 6B , which show that no significant differences in the levels of the examined proteins were observed between the dexrazoxane-treated and control group. In idarubicin treated mice, Bax, Ppp1r15a, and Parp1 were expressed in bone marrow cells at higher levels than those in untreated controls, and these genes recovered significantly with dexrazoxane pretreatment. Analysis of the other DNA damage proteins showed that the protein levels of Ogg1, Xrcc1, and Exo1 were significantly reduced in the idarubicin-injected mice compared with those of normal control mice. Interestingly, Trp53 and Atrx proteins were expressed at somewhat lower levels in idarubicin-treated mice; nevertheless, the p values for these genes did not show statistical significance. Dexrazoxane pretreatment reversed the decreased expression of Ogg1, Xrcc1, Atrx, and Exo1 genes; however, no significant change in the lowered expression of Trp53 gene was detected.
DISCUSSION
The lack of information on genotoxic effects or molecular events that can cause genomic damage via the combination of dexrazoxane and anthracyclines prompted us to conduct the current study. We investigated the impact of dexrazoxane on idarubicin-evoked genomic damage in nontumor cells along with dexrazoxane's effect on gene expression. The results revealed that dexrazoxane is not genotoxic. Additionally, it may provide an efficient way to enhance DNA repair to mitigate idarubicin-evoked genomic DNA damage in nontumor cells and lower the risk for secondary tumors. The MN assay has been used in rodents to assess unrepaired DNA damage and detects both clastogenic and aneugenic effects (Krishna and Hayashi, 2000) . Idarubicin produced a significant increase in the MNPCE and increased centromeric-negative and centromeric-positive MNPCE, indicating the induction of both clastogenic and aneugenic effects and confirming the findings of earlier animal studies (Attia, 2011; de Campos Nebel et al., 2002) . These animal studies agree with earlier human studies, where increases in both structural and numerical chromosomal aberrations were detected in cancer patients who received idarubicin-containing chemotherapy (Kim et al., 2011; Ma et al., 2011; Venizelos et al., 2007) . Both aneugenicity and clastogenicity of idarubicin, particularly in undifferentiated somatic cells, can cause the development of secondary leukemia. In this study, dexrazoxane alone caused no change in the MN formation and its pretreatment significantly and dose-dependently decreased idarubicin-evoked The values of fold down-regulation (À) or fold up-regulation (þ) were obtained by the method of 2 ÀDDC T and were normalized using the reference genes Actb, B2m, Gapdh, Gusb, and Hsp90ab1. All of the genes in the table showed statistical differences in expression (Student's t-test p < .05) when compared with that of the control group. NA, nonaltered. MNPCE formation. Furthermore, both aneugenic and clastogenic potentials evoked by idarubicin injection were decreased by dexrazoxane pretreatment, as identified by FISH assay. DNA repair and susceptibility to apoptosis are also major factors that lead to cancer. At 3 and 24 h after idarubicin treatment, marrow cells were harvested and the comet assay, which can detect early stages of DNA damage that frequently lead to genotoxicity, was performed (Collins and Azqueta, 2012) . The results of comet assay show that the levels of DNA damage observed in dexrazoxane treated mice were near those in the untreated mice. Mice exposed to idarubicin showed significant increases in the levels of DNA damage at both sampling times, in agreement with previous results (Attia, 2011; de Campos Nebel et al., 2002; Wysokinski et al., 2012) and consistent with the topoisomerase II-mediated DNA cleavage known to occur with idarubicin (Binaschi et al., 1997) . Genomic damage by idarubicin is considered its antineoplastic action, but this genotoxicity should be minimized in nontumor cells. Mice pretreated with dexrazoxane exhibited a significant reduction in DNA damages evoked by idarubicin only at 24 h. This suggests that dexrazoxane has no influence on the incidence of early DNA strand breaks induced by idarubicin treatment.
High doses of anthracyclines disrupt inner mitochondrial membrane potentials and stimulate apoptosis. In addition, when cell damage is severe and DNA repair insufficient, apoptosis-inducing downstream signaling effectors are activated, leading to cell death (Roos and Kaina, 2013) . The level of apoptosis markedly increased in the idarubicin-treated group, whereas apoptosis in the dexrazoxane and dexrazoxane/idarubicin combination groups remained low. Our results confirm earlier in vivo findings for idarubicin, in which significant increases in apoptosis were found in mice injected with idarubicin (de Campos Nebel et al., 2002) .
All clinically active anthracyclines, including idarubicin, can undergo electron reduction reactions to produce oxygen free radicals, which can damage macromolecules (Celik and Arinc, 2008; Majsterek et al., 2005) . Persistence of oxygen free radicals can lead to gene mutation and increased risk of carcinogenesis (Attia, 2010; Valko et al., 2007) . In the current work, higher levels of ROS were detected after idarubicin treatment, and increased ROS levels were associated with increased DNA damage and apoptosis. Previous reports have verified the antioxidant properties of dexrazoxane (Galetta et al., 2010; Junjing et al., 2010) . Furthermore, dexrazoxane has potent scavenging activity against not only hydroxyl free radicals, which are the typical free radicals produced from the redox reaction of iron complexes, but also peroxyl and peroxynitrite radicals. These data suggest that the antioxidant properties of dexrazoxane are not only dependent on iron chelation, although iron chelation may contribute to the decrease in iron based free radical generation (Galetta et al., 2010; Junjing et al., 2010) . Our work shows that dexrazoxane pretreatment can reduce idarubicin-evoked ROS increases. Thus, the scavenging of ROS by dexrazoxane appears to be an important mechanism against idarubicin-evoked DNA damage.
In mammals, there are at least 2 protection pathways involved in overcoming the oxidative DNA damage caused by free radicals: antioxidant defenses and DNA repair mechanisms. Previous studies revealed that dexrazoxane produced antigenotoxic effects against etoptoside, doxorubicin, and epirubicin, which were associated with increased glutathione levels (Attia et al., , 2016a . In this study, the influence of dexrazoxane in modulating the expression of DNA damage and repair genes was evaluated. The evidence to date suggests that gene expression profiles reflect underlying mechanisms of action, so that they are useful in predicting chemical genotoxicity and carcinogenicity, particularly together with conventional assays for gene mutations, clastogenicity, and aneugenicity (Waters et al., 2010) . The signaling pathway RT 2 Profiler PCR Array takes advantage of RT-qPCR performance and the ability of microarrays to identify the expression of many genes simultaneously. In the current study, idarubicin and dexrazoxane modulated the expression of genes involved in DNA damage repair. However, the gene expression profiles differed between treatments, demonstrating that these drugs modulate different genes related to the DNA damage pathway. Multiple genes involved in DNA damage and repair signaling pathways showed altered expression in dexrazoxane-treated mice, but only Topbp1 was statistically significant. Conversely, the expression profile of 84 genes involved in DNA damage revealed that DNA damage responses to idarubicin treatment did indeed occur, with 16 genes differentially expressed at statistically significant levels. When dexrazoxane was administered prior to idarubicin treatment, substantial restoration of the mRNA expression of these genes was observed. Additionally, 6 genes (Ogg1, Rad51, Terf1, Fen1, Xpc, and Xrcc6) were significantly up-regulated in dexrazoxane-pretreated mice. The mammalian cellular response to genotoxic stress is complex process including several known and probably several as yet unknown genes. In our study, the downregulation of DNA repair genes and upregulation of cell cycle arrest-and apoptosis-related genes after idarubicin treatment are in agreement with other studies of doxorubicin, another anthracycline (Mello et al., 2017) . The reduction of DNA damage repair mRNA and protein expression by idarubicin in established models of acute myeloid leukemia has been reported (Ranganathan et al., 2016) . Additionally, the down-regulation of DNA repair genes by doxorubicin was reported in human prostate cancer cells (Yuan et al., 1999) .
The array results were validated by RT-qPCR. The results indicate that the genes associated with cell cycle and apoptosis events, such as Bax, Ppp1r15a, and Trp53, were upregulated, and genes associated with DNA repair, such as Exo1, Ogg1, and Xrcc1, were downregulated in idarubicin-treated animals. It is well documented that triggering of apoptotic mechanisms is important to avoid division of cells that carry DNA-damage (Fitzwalter and Thorburn, 2015) . Substantial restorations of mRNA expression of the analyzed genes were observed in dexrazoxane-pretreated animals, which confirmed the earlier array results. We used western blots in our study to corroborate changes in the mRNA expression of a subset of genes at the protein level. The analyzed proteins were selected because they are known to have diverse and important functions in the response of cells to DNA damage. In idarubicin-treated mice, Ppp1r15a, Parp1, and Bax were expressed at significantly higher levels, and Ogg1, Exo1, Xrcc1, and Pttg1 were expressed at significantly lower levels than in untreated mice; these effects were reversed by dexrazoxane pretreatment, consistent with the array results.
Thus, the mRNAs of most of the altered genes were indeed translated into their proteins. However, some variations were noted between the array and western blotting data. These variations may have been caused by differences in the balance between protein synthesis and protein degradation compared with mRNA expression. The modulation in protein levels of these genes indicate that inhibition of DNA repair-related pathways is a potential mechanism for the idarubicin-evoked DNA damage that results in MN formation and DNA strand breaks. These results also indicate that dexrazoxane may protect genomic DNA by improving DNA repair. These animal results agree with earlier studies of animal and human cells, where anthracyclines downregulated genes implicated in DNA repair (Mello et al., 2017; Ranganathan et al., 2016; Yuan et al., 1999) . Base excision repair primarily repairs mutations caused by ROS accumulation in order to maintain genome integrity. Therefore, idarubicin may cause genomic damage via oxidative stress and the resulting, unrepaired DNA damage possibly persists due to changes in the expression of DNA repair genes. These results also indicate the potential of dexrazoxane to reverse those pathways.
CONCLUSION
Dexrazoxane can be safely co-administered with idarubicin and that pretreatment with dexrazoxane can prevent idarubicinevoked ROS generation, genomic DNA damage, and apoptosis in nontumor cells. The current results show that, in addition to cardiotoxicity, genomic damage and, consequently, development of secondary tumors should be considered as adverse effects of idarubicin that can be alleviated by dexrazoxane pretreatment. Thus, dexrazoxane may minimize secondary malignancies in cancer patients who are exposed to idarubicin.
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